BRANFORD, CT – (May 6, 2019) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company focused on novel gastrointestinal therapies that promote mucosal healing, announced today that Ron Lennox, D.Phil., has joined its Board of Directors. Dr. Lennox, a prolific biotechnology entrepreneur and investor over the last 30 years, will work with Thetis senior management as it transitions TP-317, its lead candidate in inflammatory bowel disease (IBD), into clinical development.
Gary Mathias, Co-Founder and Chief Executive Officer of Thetis commented, “Dr. Lennox will be a tremendous asset to Thetis as we advance TP-317 into the clinic. In addition to his remarkable experience in the biotechnology industry as an entrepreneur and investor, Dr. Lennox shares our belief in the promise of Resolvin-based therapies and their potential to transform the treatment of IBD and other chronic inflammatory diseases.”
“I have followed the Resolvin class for many years and believe that the technology developed by Thetis is a major advance which will enable the clinical investigation of these potent endogenous molecules,” added Dr. Lennox. “As a first-in-class Resolvin-based oral therapy, TP-317 offers a new approach for treating IBD that has prospects to promote inflammation resolution, mucosal healing and tissue repair without compromising immune function. Based on its mechanism of action and anticipated profile as a safe, oral drug, TP-317 offers attractive therapeutic prospects for IBD patients failing 5-ASA, an unaddressed segment with limited therapeutic options beyond escalating to biologics and other immunosuppressive agents that have risk of significant side effects and in many cases black box warnings.”
Over the last 30 years, Dr. Lennox has been an investor and executive in multiple early-stage life science companies. He has served on the boards of 18 companies including General Surgical Innovations (acquired by Tyco International Corp.), GeneOhm Sciences (acquired by Becton Dickinson), and Applied Molecular Evolution (acquired by Eli Lilly). He was the founding CEO of Protometrix (acquired by Life Technologies, Inc.) and CGI Pharma (acquired by Gilead), founding Chairman of Amicus Therapeutics (NASDAQ: FOLD) and Chairman of Bikam Pharma (acquired by Shire). He has invested in 11 additional companies that have had successful IPOs. He began his investment career with Hancock Venture Partners and was a founding partner at CHL Medical Partners, a Connecticut-based venture capital firm investing in the life sciences. He is an Entrepreneur in Residence with the Yale University Office of Co-operative Research and Mount Sinai Innovation Partners. Dr. Lennox holds a B.Sc. in Molecular Biology from the University of Glasgow, a D.Phil. in Cell Biology from Oxford University and an MBA from The Wharton School of the University of Pennsylvania.
About Thetis Pharmaceuticals
Thetis Pharmaceuticals is a biopharmaceutical company developing novel small molecule therapies for the treatment of IBD and other inflammatory diseases. The HEALER technology platform discovered by Thetis enables the pharmaceutical development of resolvins, a novel class of molecules with the potential to transform the treatment of chronic inflammatory diseases. Thetis’ lead candidate, TP-317, is being developed as a potential first-in-class, safe, oral therapy for IBD, including ulcerative colitis and Crohn’s disease. TP-317 is a new molecule that delivers Resolvin E1 (RvE1), a lipid mediator present in the human body that resolves inflammation and promotes mucosal tissue repair. Thetis was awarded a $2.3 million Fast Track SBIR grant from the National Institute of Health supporting TP-317 development and anticipates initiating clinical investigation in 2020.
For more information, please visit Thetis Pharmaceuticals’ website (www.thetispharma.com) and follow Thetis on Twitter (@thetispharma).
Director of Business Development